Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

by Miles, D., de haas, S., Dirix, L., Romieu, G., Chan, Arlene, Pivot, X., Tomczak, P., Provencher, L., Cortes, J., Delmar, P., Scherer, S.
Published 2013

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer

by Dent, S., Verma, Sh., Latreille, J., Rayson, D., Clemons, M., Mackey, J., Verma, Su., Lemieux, J., Provencher, L., Chia, S., Wang, B., Pritchard, K.
Published 2009

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

by Miles, D W, de Haas, S L, Dirix, L Y, Romieu, G, Chan, A, Pivot, X, Tomczak, P, Provencher, L, Cortés, J, Delmar, P R, Scherer, S J
Published 2013

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic brea...

by Miles, D., Chan, Arlene, Dirix, L., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J., Provencher, L., Puglisi, F., Harbeck, N., Steger, G., Schneeweiss, A., Wardley, A., Chlistalla, A., Romieu, G.
Published 2010

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal,...

by Eiermann, W., Pienkowski, T., Crown, J., Sadeghi, S., Chan, Arlene, Saleh, M., Sehdev, S., Provencher, L., Semiglazov, V., Press, M., Sauter, G., Lindsay, M., Riva, A., Buyse, M., Drevot, P., Taupin, H., Mackey, J.
Published 2011